Biogen will make an upfront payment in the amount of $124 million to AGTC, which includes a $30 million equity investment in AGTC at a price equal to $20.63 per share and certain prepaid research and development expenditures. Biogen will be granted a license to the XLRS and XLRP programs and the option to license discovery programs for three additional indications at the time of clinical candidate selection.
Under the collaboration, AGTC is eligible to receive upfront and milestone payments exceeding $1 billion. This includes up to $472.5 million collectively for the two lead programs, which also will carry royalties in the high single digit to mid-teen percentages of annual net sales. In addition, Biogen will make payments up to $592.5 million across the discovery programs, along with royalties in the mid single digits to low teen percentages of annual net sales.
Keep_TheFlufferQueen...get back to doing what you do best...fluffing...you know...to make up all the money you lost investing here(2 1/2 shares worth). Restore the family fortune!! All $72.50!! That's going to take a long time with you on your knees playing catch the spooge!
You've never been right once about anything Ocata related. But you sure are entertaining at times!
Celgene and Juno Announce Ten-Year Collaboration to Advance Potentially Groundbreaking Immunotherapies for Patients with Cancer and Autoimmune Diseases
Broad strategic collaboration leveraging combined immunology expertise and assets to develop and commercialize novel immunotherapies for the treatment of cancer and autoimmune diseases
Celgene gains option to commercialize Juno programs outside North America and co-promote certain programs globally
Juno gains option to co-develop and co-promote select Celgene programs
Celgene to make initial payment of approximately $1 billion which includes the purchase of ~9.1 million shares of Juno stock at $93.00 per share, with potential to increase its stake over time
Perhaps you show go and see when the FDA CBER Advisory Comittee meets re: SPA/cellular.